Overview
SS-31, also known as elamipretide, is a mitochondrial-targeted tetrapeptide that “selectively binds cardiolipin in the inner mitochondrial membrane.” This peptide stabilizes electron transport chain complexes, reduces reactive oxygen species production, and enhances ATP synthesis in metabolically active tissues.
Mechanism of Action
The peptide accumulates in the inner mitochondrial membrane where it binds to cardiolipin, “a specialized phospholipid essential for organizing electron transport chain supercomplexes.” By stabilizing these structures, SS-31 optimizes electron transport efficiency and enhances energy production while reducing oxidative stress.
Clinical Significance
SS-31 received FDA accelerated approval in 2025 as the first treatment for Barth syndrome. The TAZPOWER trial demonstrated “significant improvements in muscle strength and six-minute walk distance.” Preclinical research showed protective effects across heart failure, neurodegeneration, and age-related muscle atrophy models.
Dosage Protocol
Standard/Gradual Approach (3.0 mL reconstitution = ~10 mg/mL)
– Weeks 1-2: 5 mg (50 units) once daily
– Weeks 3-8: 10 mg (100 units) once daily
Advanced Approach (Under Medical Supervision)
– Weeks 1-2: 5 mg once daily
– Weeks 3-4: 10 mg once daily
– Weeks 5-8: 15 mg (split into two 75-unit injections)
– Weeks 9-12: 20 mg (split into two 100-unit injections)
Reconstitution Instructions
1. Draw 3.0 mL bacteriostatic water with a sterile syringe
2. Inject slowly down the vial wall (avoid vigorous shaking)
3. Gently swirl until fully dissolved
4. Label with date and refrigerate immediately at 2-8°C (35.6-46.4°F)
5. Use within 4 weeks of reconstitution
Storage Requirements
Lyophilized: Store at −20°C (−4°F) in sealed vial, protected from light and moisture
Reconstituted: Refrigerate at 2-8°C (35.6-46.4°F); do not refreeze; use within 4 weeks
Injection Protocol
– Frequency: Once daily subcutaneously at consistent time
– Angle: 45-90° depending on subcutaneous tissue thickness
– Do not aspirate before injection
– Inject slowly over 3-5 seconds
– Rotate injection sites systematically (abdomen, thighs, upper arms)
– Space injections at least 2 inches apart for doses ≥15 mg
Supplies Needed (8-12 week protocol)
– Peptide Vials: 17-35 vials depending on dosing approach
– Insulin Syringes (U-100): 56-84 syringes
– Bacteriostatic Water: 2-4 bottles (30 mL each)
– Alcohol Swabs: 112-168 swabs
Potential Benefits
– Stabilizes mitochondrial membranes and optimizes electron transport function
– Enhances ATP production and reduces oxidative stress
– Demonstrated functional improvements in Barth syndrome patients
– No significant effects on blood pressure, heart rate, or standard lab parameters
Common Side Effects
– Injection-site reactions (most common): Mild-to-moderate redness, itching, or transient discomfort; typically resolve within hours
– Approximately 80% of clinical trial participants experienced mild injection-site reactions
– No dose-limiting toxicities or serious adverse events directly attributed to SS-31
Important Considerations
– Clinical trials typically lasted 4-12 weeks; long-term safety data beyond 12 weeks is limited
– Advanced dosing (15-20 mg/day) should only be pursued under medical supervision
– For doses ≥15 mg, split into two separate subcutaneous injections at different sites
– Mild local irritation common; rotate sites systematically to prevent lipohypertrophy
– Document daily dose, injection site, and any adverse reactions for consistency
Lifestyle Support
– Nutrition: Emphasize B-vitamins, CoQ10, magnesium, and alpha-lipoic acid
– Exercise: Combine resistance training with aerobic activity to stimulate mitochondrial biogenesis
– Sleep: Prioritize 7-9 hours for cellular repair
– Stress Management: Incorporate meditation or yoga
– Avoid Mitotoxins: Minimize alcohol and environmental toxins